Skip to main content

Metabolic Health

0
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
1100%
+ 2 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
1 program
Physical InactivityN/A1 trial
Active Trials
NCT07255807Not Yet Recruiting80Est. Jun 2038
Sunshine Biopharma
Sunshine BiopharmaQC - Varennes
1 program
Power Line ProgramN/A1 trial
Active Trials
NCT06486077Completed17Est. Nov 2025
Prevail Therapeutics
1 program
TirzepatideN/APeptide1 trial
Active Trials
NCT06354101Withdrawn0Est. Jul 2023

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
2027
2028
2029
2030
2031
Novo NordiskPhysical Inactivity
Sunshine BiopharmaPower Line Program
Prevail TherapeuticsTirzepatide

Clinical Trials (3)

Total enrollment: 97 patients across 3 trials

NCT07255807Novo NordiskPhysical Inactivity

Defining the Human Insulin Resistance Molecular Network; SIGNATURE

Start: Dec 2025Est. completion: Jun 203880 patients
N/ANot Yet Recruiting
NCT06486077Sunshine BiopharmaPower Line Program

Metabolic Health 1: Power Line Evaluation; Effect Size Determination

Start: May 2025Est. completion: Nov 202517 patients
N/ACompleted
NCT06354101Prevail TherapeuticsTirzepatide

The Purpose of This Registry Study is to Learn More About Metabolic Health: Approximately 15,000 Participants Who Are Overweight or Have Obesity With or Without Metabolic Diseases Are Expected to Participate in This Registry Study.

Start: Jul 2023Est. completion: Jul 20230
N/AWithdrawn

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.